Dalpiciclib as Adjuvant Therapy for HR-positive/HER2-negative Early-stage Patients
Dalpiciclib as Adjuvant Therapy for HR-positive/HER2-negative Early-stage Patients
Not yet recruiting · NCT07101159 · Registry updated 2025-08-03Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| Dalpiciclib as Adjuvant Therapy for HR-positive/HER2-negative Early-stage Patients | Neoplasms by Site, Skin and Connective Tissue Diseases, breast disorder, breast neoplasm, neoplasm, skin disorder | Not yet recruiting | Phase 2 | 2025-08-03 | NCT07101159 |
1 results · Page 1 of 1
Organizations
Swipe the table sideways for more columns.
| Organizations | Linked trials |
|---|---|
| Fujian Cancer Hospital | 114 |
0 results · Page 1 of 1
Research sites
Swipe the table sideways for more columns.
| Research sites | City | Country | Linked trials |
|---|---|---|---|
| No products are listed yet. | |||